查看购物车
  • Traditional Chinese
  • English
  • Japanese
欧洲精准医疗市场（依生态系与国家）分析与预测（2024-2034）
市场调查报告书
商品编码
1719318

欧洲精准医疗市场（依生态系与国家）分析与预测（2024-2034）

Europe Precision Medicine Market: Focus on Ecosystem and Country - Analysis and Forecast, 2024-2034
出版日期: | 出版商: BIS Research | 英文 83 Pages | 商品交期: 1-5个工作天内

价格

欧洲精准医疗市场规模预计将从 2024 年的 407.5 亿美元成长到 2034 年的 1,187.9 亿美元，预测期内（2024-2034 年）的复合年增长率为 11.29%。

基因组学、诊断学和标靶药物的进步正在推动欧洲精准医疗领域的发展。主要驱动因素包括慢性病的增加、数位健康资源的整合以及对个人化医疗的日益关注。政府计画和研究合作伙伴支持定製药物的研发，从而为患者带来更多益处。此外，生物标记、次世代定序和人工智慧诊断的广泛使用也正在改变罕见疾病、心臟病学和肿瘤学的治疗。鑑于该地区强大的医疗基础设施和日益增强的个人化治疗意识，精准医疗正在整个医疗环境中迅速应用。

主要市场统计数据
预测期 2024-2034
2024年评估 407.5亿美元
2034年的预测 1187.9亿美元
复合年增长率 11.29%

从治疗方法到高度客製化的治疗方法，欧洲精准医疗市场正在大幅改变医疗保健格局。技术进步，特别是基因组学、次世代定序和生物标记识别领域的技术进步，使得诊断和治疗疾病的方法更加专业化。个人化医疗正在显着改善罕见遗传疾病、心血管疾病和肿瘤患者的治疗效果。欧洲各国政府透过推行积极的政策和大力投资研发，为这项变革做出了贡献。监管机构正在加快精准医疗的核准流程，同时对病患隐私和资料安全保持严格的指导方针。

製药公司、生技公司和学术机构之间的策略联盟进一步加强了市场，培育了创新和合作研究的生态系统。数位健康工具和人工智慧越来越多地被融入临床工作流程中，以提高诊断准确性并客製化治疗。儘管面临先进技术高成本、监管复杂以及需要强大的医疗保健基础设施等挑战，精准医疗的发展势头依然强劲。在公共资金和私人投资的支持下，欧洲致力于个人化医疗，正在重新定义临床实践，并将自己定位为提供以患者为中心的医疗保健的全球领导者。

遗传学、人工智慧和医疗技术的进步使得个人化治疗方案成为可能，推动欧洲精准医疗业务的快速发展。特别是在肿瘤学和罕见疾病领域，次世代定序与生物标记开发相结合，有助于早期发现和加护治疗。由于政府计划、医疗创新资金增加以及合作研究活动，市场正在扩大。由于人口老化、慢性病盛行率上升以及对更有效治疗方案的需求，市场正在成长。然而，高成本、复杂的法律体制和资料隐私问题阻碍了其广泛采用。将精准医疗纳入传统医疗保健系统需要大量的基础设施投资和病患教育。儘管存在这些障碍，但技术发展以及生物技术、製药和学术机构之间的策略联盟正在为更具凝聚力和更有效的精准医疗生态系统打开大门。

产品/创新策略：本报告深入探讨精准医疗领域的最新技术进步，使公司能够推动创新并开发符合市场需求的尖端产品。

成长/行销策略：我们提供全面的市场分析并确定关键的成长机会，为您的组织提供製定有针对性的行销策略和有效扩大市场影响力的知识。

竞争策略：彻底分析竞争格局有助于了解竞争对手的优势和劣势，并有助于制定有效的策略以获得市场竞争优势。

本报告研究了欧洲精准医疗市场，提供了市场概况、生态系统和国家趋势以及参与市场的公司概况。

目录

第一章 市场概述

  • 市场定义
  • 精准医疗：创造以病人为中心的医疗的前沿
  • 精准医疗：重新构想「一刀切」的治疗方法，实现个人治疗方法
  • 倡议和计划
  • 精准医疗：实行技术与应用

第二章市场：产业展望

  • 精准医疗市场：生态系分析
  • 市场趋势
  • 业界考察
  • 生态系摘要

第三章 区域

  • 概述
  • 欧洲
    • 区域概况
    • 市场成长动力
    • 成长抑制因素
    • 德国
    • 法国
    • 义大利
    • 英国
    • 西班牙
    • 其他的

第四章 竞争格局

  • 竞争格局
  • 公司简介
    • Almac Group
    • ANGLE plc
    • F. Hoffmann-La Roche Ltd.
    • Merck KGaA
    • QIAGEN NV
    • bioMerieux SA
    • Sanofi SA
    • Randox Laboratories Ltd.
    • GSK plc
    • Novartis AG
    • Menarini Silicon Biosystems

第五章调查方法

Product Code: BHP2770SS

Introduction to Europe Precision Medicine Market

The Europe precision medicine market is projected to reach $118.79 billion by 2034 from $40.75 billion in 2024, at a CAGR of 11.29% during the forecast period of 2024-2034. Advances in genomes, diagnostics, and targeted medicines are driving the precision medicine sector in Europe. Key factors include the growing prevalence of chronic diseases, the integration of digital health resources, and an increased emphasis on personalised healthcare. The creation of customised medicines is being aided by government programs and research partnerships, which is increasing patient results. Furthermore, the care of uncommon illnesses, cardiology, and oncology is changing due to the extensive use of biomarkers, next-generation sequencing, and AI-powered diagnostics. Precision medicine is being adopted more quickly in a variety of healthcare settings thanks to the region's robust healthcare infrastructure and rising awareness of personalised treatment.

Market Introduction

KEY MARKET STATISTICS
Forecast Period2024 - 2034
2024 Evaluation$40.75 Billion
2034 Forecast$118.79 Billion
CAGR11.29%

From one-size-fits-all therapies to highly customised therapeutic options, the precision medicine market in Europe is drastically changing the healthcare environment. More specialised methods of diagnosing and treating diseases have been made possible by technological advancements, especially in the fields of genomics, next-generation sequencing, and biomarker identification. Personalised therapies are greatly improving patient outcomes in uncommon genetic disorders, cardiovascular diseases, and oncology. By promoting policies that are helpful and making significant investments in research and development, European governments have been instrumental in this change. While maintaining strict guidelines for patient privacy and data security, regulatory bodies are expediting the approval procedures for precision treatments.

The market is further bolstered by strategic alliances among pharmaceutical companies, biotech firms, and academic institutions, fostering an ecosystem of innovation and collaborative research. Digital health tools and artificial intelligence are increasingly integrated into clinical workflows, enhancing diagnostic accuracy and treatment customization. Despite challenges such as the high cost of advanced technologies, regulatory complexities, and the need for robust healthcare infrastructure, the momentum behind precision medicine remains strong. Europe's commitment to personalized healthcare, underpinned by public funding and private investment, positions the region as a global leader in redefining clinical practices and delivering patient-centric care.

Market Segmentation

Segmentation 1: by Ecosystem

  • Applied Science
  • Precision Diagnostics
  • Digital Health and Information Technology
  • Precision Therapeutics

Segmentation 2: by Region

  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Rest-of-Europe

Market Trends, Drivers and Challenges of Europe Precision Medicine Market

Advances in genetics, artificial intelligence, and health technology that allow for individualised treatment options are driving a rapid evolution of the precision medicine business in Europe. Especially in oncology and uncommon disorders, the combination of next-generation sequencing and biomarker development is promoting early detection and focused treatments. The market is expanding thanks to government programs, more financing for healthcare innovation, and cooperative research activities. The market is expanding due to ageing populations, an increase in the prevalence of chronic diseases, and a need for more efficient treatment plans. However, obstacles to wider adoption include expensive costs, intricate legal frameworks, and data privacy issues. It takes large infrastructure investments and patient education to incorporate precision medicine into traditional healthcare systems. Notwithstanding these obstacles, technological developments and strategic alliances between biotech, pharmaceutical, and academic organisations are opening the door to a more cohesive and effective precision medicine ecosystem, which will eventually lead to better patient outcomes and a shift in Europe towards individualised healthcare solutions.

How can this report add value to an organization?

Product/Innovation Strategy: The report offers in-depth insights into the latest technological advancements in precision medicine, enabling organizations to drive innovation and develop cutting-edge products tailored to market needs.

Growth/Marketing Strategy: By providing comprehensive market analysis and identifying key growth opportunities, the report equips organizations with the knowledge to craft targeted marketing strategies and expand their market presence effectively.

Competitive Strategy: The report includes a thorough competitive landscape analysis, helping organizations understand their competitors' strengths and weaknesses and allowing them to strategize effectively to gain a competitive edge in the market.

Key Market Players and Competition Synopsis

Profiled companies have been selected based on inputs gathered from primary experts, as well as analyzing company coverage, product portfolio, and market penetration.

Some prominent names established in this market are:

  • Almac Group Ltd.
  • ANGLE plc
  • F. Hoffmann-La Roche Ltd.
  • Merck KGaA
  • QIAGEN N.V.

Table of Contents

1 Market Overview

  • 1.1 Market Definition
  • 1.2 Precision Medicine: A Frontier in the Genesis of Patient-Centric Medicine
  • 1.3 Precision Medicine: Remodeling the One-Size-Fits-All Theory to Individually Tailored Therapy
  • 1.4 Initiatives and Programs
  • 1.5 Precision Medicine: Enabling Technologies and Applications
    • 1.5.1 Innovators
      • 1.5.1.1 3D DNA Printing
        • 1.5.1.1.1 Introduction
        • 1.5.1.1.2 Role of 3D DNA Printing
      • 1.5.1.2 RNA-Seq
        • 1.5.1.2.1 Introduction
        • 1.5.1.2.2 Role of RNA-Seq in Precision Medicine
        • 1.5.1.2.3 Key Players
      • 1.5.1.3 4D Molecular Imaging
        • 1.5.1.3.1 Introduction
        • 1.5.1.3.2 Role of 4D Molecular Imaging in Precision Medicine
        • 1.5.1.3.3 Key Players
    • 1.5.2 Early Adopters
      • 1.5.2.1 CRISPR
        • 1.5.2.1.1 Introduction
        • 1.5.2.1.2 Role of CRISPR in Precision Medicine
        • 1.5.2.1.3 Key Players
      • 1.5.2.2 Blockchain
        • 1.5.2.2.1 Introduction
        • 1.5.2.2.2 Role of Blockchain in Precision Medicine
        • 1.5.2.2.3 Key Players
      • 1.5.2.3 Imaging Informatics
        • 1.5.2.3.1 Introduction
        • 1.5.2.3.2 Role of Imaging Informatics in Precision Medicine
        • 1.5.2.3.3 Key Players
    • 1.5.3 Early Majority
      • 1.5.3.1 Artificial Intelligence (AI)
        • 1.5.3.1.1 Introduction
        • 1.5.3.1.2 Role of Artificial Intelligence in Precision Medicine
        • 1.5.3.1.3 Key Players
      • 1.5.3.2 Circulating Free DNA (cfDNA)
        • 1.5.3.2.1 Introduction
        • 1.5.3.2.2 Role of cfDNA in Precision Medicine
        • 1.5.3.2.3 Key Players
      • 1.5.3.3 Big Data
        • 1.5.3.3.1 Introduction
        • 1.5.3.3.2 Role of Big Data in Precision Medicine
        • 1.5.3.3.3 Key Players
      • 1.5.3.4 Next-Generation Sequencing (NGS)
        • 1.5.3.4.1 Introduction
        • 1.5.3.4.2 Role of NGS in Precision Medicine
        • 1.5.3.4.3 Key Players
      • 1.5.3.5 Health Informatics
        • 1.5.3.5.1 Introduction
        • 1.5.3.5.2 Role of Health Informatics in Precision Medicine
        • 1.5.3.5.3 Key players
      • 1.5.3.6 Bioinformatics
        • 1.5.3.6.1 Introduction
        • 1.5.3.6.2 Role of Bioinformatics in Precision Medicine
        • 1.5.3.6.3 Key Players
    • 1.5.4 Late Majority
      • 1.5.4.1 Polymerase Chain Reactions (PCR)
        • 1.5.4.1.1 Introduction
        • 1.5.4.1.2 Role of PCR in Precision Medicine
        • 1.5.4.1.3 Key players
      • 1.5.4.2 Microarray
        • 1.5.4.2.1 Role of Microarray in Precision Medicine
        • 1.5.4.2.2 Key Players

2 Market: Industry Outlook

  • 2.1 Precision Medicine Market: Ecosystem Analysis
  • 2.2 Market Trends
    • 2.2.1 Integrating Advanced Imaging for Enhanced Diagnostics and Treatment
    • 2.2.2 Emergence of Biobanks as a Cornerstone of Precision Medicine
  • 2.3 Industry Insights
    • 2.3.1 Patent Analysis
    • 2.3.2 Pipeline Analysis
    • 2.3.3 Legal Requirements and Framework by the EMA
  • 2.4 Ecosystem Summary

3 Region

  • 3.1 Overview
  • 3.2 Europe
    • 3.2.1 Regional Overview
    • 3.2.2 Driving Factors for Market Growth
    • 3.2.3 Factors Challenging the Market
      • 3.2.3.1 Europe Precision Medicine Market (by Ecosystem),
    • 3.2.4 Germany
      • 3.2.4.1 Germany Precision Medicine Market (by Ecosystem),
    • 3.2.5 France
      • 3.2.5.1 France Precision Medicine Market (by Ecosystem)
    • 3.2.6 Italy
      • 3.2.6.1 Italy Precision Medicine Market (by Ecosystem),
    • 3.2.7 U.K.
      • 3.2.7.1 U.K. Precision Medicine Market (by Ecosystem),
    • 3.2.8 Spain
      • 3.2.8.1 Spain. Precision Medicine Market (by Ecosystem),
    • 3.2.9 Rest-of-Europe
      • 3.2.9.1 Rest-of-Europe Precision Medicine Market (by Ecosystem)

4 Competitive Landscape

  • 4.1 Competitive Landscape
    • 4.1.1 Synergistic Activities
  • 4.2 Company Profiles
    • 4.2.1 Almac Group
      • 4.2.1.1 Overview
      • 4.2.1.2 Top Products/Services
      • 4.2.1.3 Top Competitors
      • 4.2.1.4 Analyst View
    • 4.2.2 ANGLE plc
      • 4.2.2.1 Overview
      • 4.2.2.2 Top Products
      • 4.2.2.3 Top Competitors
      • 4.2.2.4 Analyst View
    • 4.2.3 F. Hoffmann-La Roche Ltd.
      • 4.2.3.1 Overview
      • 4.2.3.2 Top Products
      • 4.2.3.3 Top Competitors
      • 4.2.3.4 Analyst View
    • 4.2.4 Merck KGaA
      • 4.2.4.1 Overview
      • 4.2.4.2 Top Products
      • 4.2.4.3 Top Competitors
      • 4.2.4.4 Analyst View
    • 4.2.5 QIAGEN N.V.
      • 4.2.5.1 Overview
      • 4.2.5.2 Top Products
      • 4.2.5.3 Top Competitors
      • 4.2.5.4 Analyst View
    • 4.2.6 bioMerieux SA
      • 4.2.6.1 Overview
      • 4.2.6.2 Top Products
      • 4.2.6.3 Top Competitors
      • 4.2.6.4 Analyst View
    • 4.2.7 Sanofi S.A.
      • 4.2.7.1 Overview
      • 4.2.7.2 Top Products
      • 4.2.7.3 Top Competitors
      • 4.2.7.4 Analyst View
    • 4.2.8 Randox Laboratories Ltd.
      • 4.2.8.1 Overview
      • 4.2.8.2 Top Products
      • 4.2.8.3 Top Competitors
      • 4.2.8.4 Analyst View
    • 4.2.9 GSK plc
      • 4.2.9.1 Overview
      • 4.2.9.2 Top Products
      • 4.2.9.3 Top Competitors
      • 4.2.9.4 Analyst View
    • 4.2.10 Novartis AG
      • 4.2.10.1 Overview
      • 4.2.10.2 Top Products
      • 4.2.10.3 Top Competitors
      • 4.2.10.4 Analyst View
    • 4.2.11 Menarini Silicon Biosystems
      • 4.2.11.1 Overview
      • 4.2.11.2 Top Products
      • 4.2.11.3 Top Competitors
      • 4.2.11.4 Analyst View

5 Research Methodology

  • 5.1 Precision Medicine Market: Research Methodology
    • 5.1.1 Data Sources
      • 5.1.1.1 Primary Data Sources
      • 5.1.1.2 Secondary Data Sources
    • 5.1.2 Data Triangulation
  • 5.2 Market Estimation and Forecast

List of Figures

  • Figure 1: Europe Precision Medicine Market, $Billion, 2023, 2028, and 2034
  • Figure 2: Precision Medicine: Treatment Tailored to an Individual's Genetic Structure
  • Figure 3: Precision Medicine - a Multi-Faceted Approach to Patient Care
  • Figure 4: Decreasing Cost ($) and Increasing Output (TB) of Genome Sequencing, 2009-2025
  • Figure 5: Precision Medicine Market (by Region), $Billion, 2023, 2028, and 2034
  • Figure 6: Europe Precision Medicine Market (by Ecosystem), $Billion, 2023, 2028, and 2034
  • Figure 7: Precision Medicine Approach
  • Figure 8: Evolution of Precision Medicine Technology
  • Figure 9: Precision Medicine: Enabling Technologies and Applications
  • Figure 10: Structured Big Data Reporting Benefits
  • Figure 11: Generalized Process for the Microarray
  • Figure 12: Stakeholders in Precision Medicine
  • Figure 13: Number of Patents Files, 2020-2024
  • Figure 14: Precision Medicine by Top Patent Owner
  • Figure 15: Europe Precision Medicine Market, $Billion, 2023-2034
  • Figure 16: Germany Precision Medicine Market, $Billion, 2023-2034
  • Figure 17: France Precision Medicine Market, $Billion, 2023-2034
  • Figure 18: Italy Precision Medicine Market, $Billion, 2023-2034
  • Figure 19: U.K. Precision Medicine Market, $Billion, 2023-2034
  • Figure 20: Spain Precision Medicine Market, $Billion, 2023-2034
  • Figure 21: Rest of Europe Precision Medicine Market, $Billion, 2023-2034
  • Figure 22: Synergistic Activities, by Company (January 2020- January 2025)
  • Figure 23: Synergistic Activities, by Type (January 2020- January 2025)
  • Figure 24: Data Triangulation
  • Figure 25: Top-Down and Bottom-Up Approach

List of Tables

  • Table 1: Market Snapshot
  • Table 2: Application
  • Table 3: Pipeline Analysis (by Company)
  • Table 4: Pipeline Analysis (by Product)
  • Table 5: Precision Medicine Drugs Pipeline Analysis
  • Table 6: Ecosystem Summary
  • Table 7: Precision Medicine Market (by Region), $Million, 2023-2034
  • Table 8: Europe Precision Medicine Market (by Ecosystem), $Billion, 2023-2034
  • Table 9: Germany Precision Medicine Market (by Ecosystem), $Billion, 2023-2034
  • Table 10: France Precision Medicine Market (by Ecosystem), $Billion, 2023-2034
  • Table 11: Italy Precision Medicine Market (by Ecosystem), $Billion, 2023-2034
  • Table 12: Funding Scenario in Universities
  • Table 13: U.K. Precision Medicine Market (by Ecosystem), $Billion, 2023-2034
  • Table 14: Spain. Precision Medicine Market (by Ecosystem), $Billion, 2023-2034
  • Table 15: Rest-of-Europe Precision Medicine Market (by Ecosystem), $Billion, 2023-2034